On January 17 – 19, 2023, ELPA attended the MICROB-PREDICT General Assembly as one of the project’s partners. ELPA President Marko Korenjak presented the communication and dissemination activities and data for 2022. He also explained how social media could support academic careers during a workshop on1 this topic. MICROB-PREDICT aims at developing personalised, microbiome-based treatment strategies to prevent and treat decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and reduce mortality by investigating the human gut microbiome. The goal is to identify predictors and mechanisms associated with the development of decompensated cirrhosis and its progression to ACLF. The need for personalised treatment strategies becomes apparent when considering that there are substantial, yet still largely unexplained, individual differences in developing decompensated cirrhosis and ACLF. At the same time, this observation bears the chance for more effective, more individualised and more targeted treatments.